Aflibercept
| Evidence Level: L5 | Predicted Indications: 54 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Aflibercept |
| DrugBank ID | DB08885 |
| Brand Names (EU) | Eyluxvi, Opuviz, Yesafili, Zaltrap |
| Evidence Level | L5 |
| Predicted Indications | 54 |
| Top Prediction Score | 99.38% |
Approved Indication (EMA)
Treatment of metastatic colorectal cancer (MCRC).
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | esotropia | 99.38% | DL |
| 2 | esophageal varices with bleeding | 97.56% | DL |
| 3 | esophageal varices without bleeding | 97.56% | DL |
| 4 | varicose disease | 96.95% | DL |
| 5 | urethral calculus | 95.97% | DL |
| 6 | adenosine deaminase deficiency | 95.76% | DL |
| 7 | hemorrhagic disease of newborn | 95.56% | DL |
| 8 | ectomesenchymoma | 94.52% | DL |
| 9 | malignant cutaneous granular cell skin tumor | 94.51% | DL |
| 10 | middle ear neuroendocrine tumor | 94.42% | DL |
| 11 | reticular dysgenesis | 94.34% | DL |
| 12 | severe combined immunodeficiency due to LCK deficiency | 94.19% | DL |
| 13 | human herpesvirus 8-related tumor | 94.13% | DL |
| 14 | lung fibrosis-immunodeficiency-46,XX gonadal dysgenesis syndrome | 93.68% | DL |
| 15 | non-severe combined immunodeficiency | 93.24% | DL |
| 16 | T-B+ severe combined immunodeficiency due to CD45 deficiency | 93.07% | DL |
| 17 | anemia of prematurity | 93.01% | DL |
| 18 | T-B+ severe combined immunodeficiency due to gamma chain deficiency | 93.00% | DL |
| 19 | Immunoerythromyeloid hypoplasia | 92.99% | DL |
| 20 | lipoma of the conjunctiva | 92.45% | DL |
Showing top 20 of 54 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.